{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T12:53:54Z","timestamp":1794920034057,"version":"4.9.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Zenyaku Kogyo Co., Ltd.","award":["JSKDC10"],"award-info":[{"award-number":["JSKDC10"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Rituximab maintains remission of complicated frequently relapsing or steroid-dependent nephrotic syndrome (FRNS\/SDNS) by depleting peripheral B cells, but most patients eventually experience relapses after B cell recovery. We performed a multicenter, double-blind, randomized, placebo-controlled trial to assess rituximab\u2019s efficacy and safety for childhood-onset uncomplicated FRNS\/SDNS (without prior treatment with glucocorticoid-sparing immunosuppressive agents) with a follow-up study to assess rituximab\u2019s long-term effect after B cell recovery. Patients were randomly assigned to receive either rituximab (375\u00a0mg\/m<jats:sup>2<\/jats:sup>, maximum 500\u00a0mg, once weekly for 2\u00a0weeks) or placebo. The primary endpoint was the relapse-free period. Of 43 randomized patients, 40 received the intervention (18 rituximab, 22 placebo). The relapse-free period during the 1-year trial was significantly longer in the rituximab vs. placebo groups (median: 285 vs. 81\u00a0days; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Infusion reactions were more frequent in the rituximab group (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), with no difference in adverse events incidence between the groups. Interestingly, the follow-up study demonstrated markedly higher 3-year cumulative relapse-free survival probability without further treatments in the rituximab vs. placebo groups (38% vs. 9%). A mini-systematic review with meta-analyses supported the findings. Rituximab is effective and well-tolerated, potentially leading to long-term remission with substantially high rates after B cell recovery for childhood-onset uncomplicated FRNS\/SDNS.<\/jats:p>\n          <jats:p>\n            <jats:italic>Trial registration<\/jats:italic> JSKDC10, Clinical Trials Registry ID: jRCT1091220380; JSKDC10 follow-up study, Clinical Trials Registry ID: jRCT1050230024<\/jats:p>","DOI":"10.1038\/s41598-025-19214-0","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T09:03:35Z","timestamp":1760087015000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Rituximab-induced long-term remission in childhood-onset, uncomplicated, frequently relapsing or steroid-dependent nephrotic syndrome: a randomized, placebo-controlled trial and a follow-up study"],"prefix":"10.1038","volume":"15","author":[{"given":"Kazumoto","family":"Iijima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayumi","family":"Sako","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Horinouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiko","family":"Yamamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riku","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasufumi","family":"Ohtsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Kamei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryojiro","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Kano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuo","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Shima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamaki","family":"Morohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Inaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichiro","family":"Fujinaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Oka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kaito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihide","family":"Konishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"China","family":"Nagano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Nakanishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Ishikura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidefumi","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Marco","family":"Ghiggeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rintaro","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Omori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kandai","family":"Nozu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Japanese Study Group of Kidney Disease in Children JSKDC10 Study","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nana","family":"Sakakibara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Kitakado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chika","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Sawai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuna","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoko","family":"Ichioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiki","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Hataya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoko","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikako","family":"Terano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoaki","family":"Mikami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Inoguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouki","family":"Tomari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Akamine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoichiro","family":"Shirane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taishi","family":"Nada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Kanamori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikako","family":"Kamae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Inaguma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhi","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Uchimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Clinical Trial Steering Committee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kandai","family":"Nozu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayumi","family":"Sako","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Independent Data and Safety Monitoring Committee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoshi","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nao","family":"Tsuchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Oba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,10]]},"reference":[{"key":"19214_CR1","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/978-3-030-52719-8_92","volume-title":"Pediatric Nephrology","author":"K Iijima","year":"2022","unstructured":"Iijima, K., Swiatecka-Urban, A., Niaudet, P. & Bagga, A. Steroid-sensitive nephrotic syndrome. In Pediatric Nephrology (eds Emma, F. et al.) 351\u2013386 (Springer, Berlin, 2022). https:\/\/doi.org\/10.1007\/978-3-030-52719-8_92."},{"key":"19214_CR2","doi-asserted-by":"publisher","unstructured":"Trautmann A, at al.; International Pediatric Nephrology Association. IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome. Pediatr. Nephrol. 38, 877\u2013919 (2023). https:\/\/doi.org\/10.1007\/s00467-022-05739-3.","DOI":"10.1007\/s00467-022-05739-3"},{"key":"19214_CR3","doi-asserted-by":"publisher","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. Suppl. 100, S1\u2013S276 (2021). https:\/\/doi.org\/10.1016\/j.kint.2021.05.021.","DOI":"10.1016\/j.kint.2021.05.021"},{"key":"19214_CR4","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/S0140-6736(23)01051-6","volume":"402","author":"M Vivarelli","year":"2023","unstructured":"Vivarelli, M., Gibson, K., Sinha, A. & Boyer, O. Childhood nephrotic syndrome. Lancet 402, 809\u2013824. https:\/\/doi.org\/10.1016\/S0140-6736(23)01051-6 (2023).","journal-title":"Lancet"},{"key":"19214_CR5","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s00467-018-4071-7","volume":"34","author":"M Yadav","year":"2019","unstructured":"Yadav, M., Sinha, A., Khandelwal, P., Hari, P. & Bagga, A. Efficacy of low-dose daily versus alternate-day prednisolone in frequently relapsing nephrotic syndrome: An open-label randomized controlled trial. Pediatr. Nephrol. 34, 829\u2013835. https:\/\/doi.org\/10.1007\/s00467-018-4071-7 (2019).","journal-title":"Pediatr. Nephrol."},{"key":"19214_CR6","doi-asserted-by":"publisher","unstructured":"Iijima K, et al.; Japanese Study Group of Kidney Disease in Children. Mycophenolate mofetil after rituximab for childhood-onset complicated frequently-relapsing or steroid-dependent nephrotic syndrome. J. Am. Soc. Nephrol. 33, 401\u2013419 (2022). https:\/\/doi.org\/10.1681\/ASN.2021050643.","DOI":"10.1681\/ASN.2021050643"},{"key":"19214_CR7","doi-asserted-by":"publisher","unstructured":"Ishikura K, et al.; Japanese Study Group of Renal Disease in Children. Two-year follow-up of a prospective clinical trial of cyclosporine for frequently relapsing nephrotic syndrome in children. Clin. J. Am. Soc. Nephrol. 7, 1576\u20131583 (2012). https:\/\/doi.org\/10.2215\/CJN.00110112.","DOI":"10.2215\/CJN.00110112"},{"key":"19214_CR8","doi-asserted-by":"publisher","first-page":"CD002290","DOI":"10.1002\/14651858.CD002290.pub5","volume":"4","author":"NG Larkins","year":"2020","unstructured":"Larkins, N. G., Liu, I. D., Willis, N. S., Craig, J. C. & Hodson, E. M. Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children. Cochrane Database Syst. Rev. 4, CD002290. https:\/\/doi.org\/10.1002\/14651858.CD002290.pub5 (2020).","journal-title":"Cochrane Database Syst. Rev."},{"key":"19214_CR9","doi-asserted-by":"publisher","unstructured":"Hamasaki Y, et al.; for Japanese Study Group of Renal Disease in Children. Prospective 5-year follow-up of cyclosporine treatment in children with steroid-resistant nephrosis. Pediatr Nephrol. 28, 765\u2013771 (2013). https:\/\/doi.org\/10.1007\/s00467-012-2393-4.","DOI":"10.1007\/s00467-012-2393-4"},{"key":"19214_CR10","doi-asserted-by":"publisher","unstructured":"Iijima K, et al. Rituximab for Childhood-onset Refractory Nephrotic Syndrome (RCRNS) Study Group. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 384, 1273\u20131281 (2014). https:\/\/doi.org\/10.1016\/S0140-6736(14)60541-9.","DOI":"10.1016\/S0140-6736(14)60541-9"},{"key":"19214_CR11","doi-asserted-by":"publisher","first-page":"178","DOI":"10.3389\/fped.2019.00178","volume":"7","author":"M Kallash","year":"2019","unstructured":"Kallash, M., Smoyer, W. E. & Mahan, J. D. Rituximab use in the management of childhood nephrotic syndrome. Front. Pediatr. 7, 178. https:\/\/doi.org\/10.3389\/fped.2019.00178 (2019).","journal-title":"Front. Pediatr."},{"key":"19214_CR12","unstructured":"Vivarelli, M. & Desch\u00eanes, G. Idiopathic Nephrotic syndrome Working Group Report, 2016. http:\/\/www.espn-online.org\/wp-content\/uploads\/b_upload\/IdiopathicNephroticsyndromeWorkingGroupReport2016.pdf (accessed Dec 22, 2023)."},{"key":"19214_CR13","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1681\/ASN.2014080799","volume":"26","author":"P Ravani","year":"2015","unstructured":"Ravani, P. et al. Rituximab in children with steroid-dependent nephrotic syndrome: A multicenter, open-label, noninferiority, randomized controlled trial. J. Am. Soc. Nephrol. 26, 2259\u20132266. https:\/\/doi.org\/10.1681\/ASN.2014080799 (2015).","journal-title":"J. Am. Soc. Nephrol."},{"key":"19214_CR14","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1001\/jamapediatrics.2018.1323","volume":"172","author":"B Basu","year":"2018","unstructured":"Basu, B. et al. Efficacy of rituximab vs tacrolimus in pediatric corticosteroid-dependent nephrotic syndrome: A randomized clinical trial. JAMA Pediatr. 172, 757\u2013764. https:\/\/doi.org\/10.1001\/jamapediatrics.2018.1323 (2018).","journal-title":"JAMA Pediatr."},{"key":"19214_CR15","doi-asserted-by":"publisher","unstructured":"Kamei K, et al.; Rituximab for Childhood-onset Refractory Nephrotic Syndrome (RCRNS) Study Group. Long-term outcome of childhood-onset complicated nephrotic syndrome after a multicenter, double-blind, randomized, placebo-controlled trial of rituximab. Pediatr. Nephrol. 32, 2071\u20132078 (2017). https:\/\/doi.org\/10.1007\/s00467-017-3718-0.","DOI":"10.1007\/s00467-017-3718-0"},{"key":"19214_CR16","doi-asserted-by":"publisher","unstructured":"Ishikura K, et al.; Japanese Society for Pediatric Nephrology. Clinical practice guideline for pediatric idiopathic nephrotic syndrome 2013: medical therapy. Clin. Exp. Nephrol.19, 6\u201333 (2015). https:\/\/doi.org\/10.1007\/s10157-014-1030-x.","DOI":"10.1007\/s10157-014-1030-x"},{"key":"19214_CR17","doi-asserted-by":"publisher","first-page":"332","DOI":"10.2215\/CJN.05000516","volume":"12","author":"M Vivarelli","year":"2017","unstructured":"Vivarelli, M., Massella, L., Ruggiero, B. & Emma, F. Minimal change disease. Clin. J. Am. Soc. Nephrol. 12, 332\u2013345. https:\/\/doi.org\/10.2215\/CJN.05000516 (2017).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"19214_CR18","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2215\/CJN.08570722","volume":"18","author":"EY Chan","year":"2023","unstructured":"Chan, E. Y. et al. Use of rituximab in childhood idiopathic nephrotic syndrome. Clin. J. Am. Soc. Nephrol. 18, 533\u2013548. https:\/\/doi.org\/10.2215\/CJN.08570722 (2023).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"19214_CR19","doi-asserted-by":"publisher","unstructured":"Zurowska A, et al.; ESPN Glomerulonephritis Working Group. Rituximab-associated hypogammaglobulinemia in children with idiopathic nephrotic syndrome: results of an ESPN survey. Pediatr. Nephrol. 38, 3035\u20133042 (2023). https:\/\/doi.org\/10.1007\/s00467-023-05913-1.","DOI":"10.1007\/s00467-023-05913-1"},{"key":"19214_CR20","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3339\/jkspn.2012.16.2.138","volume":"16","author":"J Lee","year":"2012","unstructured":"Lee, J. et al. Kikuchi-Fujimoto disease, a possible complication of rituximab treatment. J. Korean Soc. Pediatr. Nephrol. 16, 138\u2013141 (2012).","journal-title":"J. Korean Soc. Pediatr. Nephrol."},{"key":"19214_CR21","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1007\/s00467-020-04540-4","volume":"35","author":"P Ravani","year":"2020","unstructured":"Ravani, P. et al. Rituximab for very low dose steroid-dependent nephrotic syndrome in children: a randomized controlled study. Pediatr. Nephrol. 35, 1437\u20131444. https:\/\/doi.org\/10.1007\/s00467-020-04540-4 (2020).","journal-title":"Pediatr. Nephrol."},{"key":"19214_CR22","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1016\/j.ekir.2023.05.022","volume":"8","author":"B Basu","year":"2023","unstructured":"Basu, B. et al. Long-term efficacy and safety of rituximab versus tacrolimus in children with steroid dependent nephrotic syndrome. Kidney Int. Rep. 8, 1575\u20131584. https:\/\/doi.org\/10.1016\/j.ekir.2023.05.022 (2023).","journal-title":"Kidney Int. Rep."},{"key":"19214_CR23","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1016\/j.ekir.2024.02.1395","volume":"9","author":"J Liu","year":"2024","unstructured":"Liu, J. et al. Early rituximab as an add-on therapy in children with the initial episode of nephrotic syndrome. Kidney Int. Rep. 9, 1220\u20131227. https:\/\/doi.org\/10.1016\/j.ekir.2024.02.1395 (2024).","journal-title":"Kidney Int. Rep."},{"key":"19214_CR24","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00467-022-05520-6","volume":"38","author":"AM McKay","year":"2023","unstructured":"McKay, A. M., Parekh, R. S. & Noone, D. Therapeutic trials in difficult to treat steroid sensitive nephrotic syndrome: challenges and future directions. Pediatr. Nephrol. 38, 17\u201334. https:\/\/doi.org\/10.1007\/s00467-022-05520-6 (2023).","journal-title":"Pediatr. Nephrol."},{"key":"19214_CR25","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1681\/ASN.2021060794","volume":"33","author":"AJB Watts","year":"2022","unstructured":"Watts, A. J. B. et al. Discovery of autoantibodies targeting nephrin in minimal change disease supports a novel autoimmune etiology. J. Am. Soc. Nephrol. 33, 238\u2013252. https:\/\/doi.org\/10.1681\/ASN.2021060794 (2022).","journal-title":"J. Am. Soc. Nephrol."},{"key":"19214_CR26","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s00467-023-06107-5","volume":"39","author":"T Horinouchi","year":"2024","unstructured":"Horinouchi, T., Nagano, C. & Watts, A. J. B. Anti-nephrin antibodies in steroid-sensitive nephrotic syndrome in Japanese children. Pediatr. Nephrol. 39, 337. https:\/\/doi.org\/10.1007\/s00467-023-06107-5 (2024).","journal-title":"Pediatr. Nephrol."},{"key":"19214_CR27","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMoa2314471","volume":"391","author":"FE Hengel","year":"2024","unstructured":"Hengel, F. E. et al. International society of glomerular disease. Autoantibodies Targeting Nephrin in Podocytopathies. N. Engl. J. Med. 391, 422\u2013433. https:\/\/doi.org\/10.1056\/NEJMoa2314471 (2024).","journal-title":"N. Engl. J. Med."},{"key":"19214_CR28","doi-asserted-by":"publisher","first-page":"85ra46","DOI":"10.1126\/scitranslmed.3002231","volume":"3","author":"A Fornoni","year":"2011","unstructured":"Fornoni, A. et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci. Transl. Med. 3, 85ra46. https:\/\/doi.org\/10.1126\/scitranslmed.3002231 (2011).","journal-title":"Sci. Transl. Med."},{"key":"19214_CR29","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1681\/ASN.2021040561","volume":"32","author":"P Ravani","year":"2021","unstructured":"Ravani, P. et al. Human or chimeric monoclonal anti-CD20 antibodies for children with nephrotic syndrome: A superiority randomized trial. J. Am. Soc. Nephrol. 32, 2652\u20132663. https:\/\/doi.org\/10.1681\/ASN.2021040561 (2021).","journal-title":"J. Am. Soc. Nephrol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-19214-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-19214-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-19214-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T09:03:37Z","timestamp":1760087017000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-19214-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,10]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["19214"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-19214-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,10]]},"assertion":[{"value":"26 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"KIi reports a research grant for clinical trials and clinical research from Zenyaku Kogyo Co. Ltd. to his institution; consulting fees from Kyowa Kirin Co. Ltd., and Chugai Pharmaceutical Co., Ltd.; honoraria for manuscript writing from Zenyaku Kogyo Co. Ltd.; payment for expert testimony to my institution from Zenyaku Kogyo Co. Ltd.; and serves as a member of the advisory board of Kyowa Kirin Co. Ltd. and Chugai Pharmaceutical Co., Ltd.. MS reports grants for clinical trials and development promotion network from Japan Agency for Medical Research and Development; honoraria for lectures from Chugai Pharmaceutical Co., Ltd.; payment for expert testimony to her institution from Zenyaku Kogyo Co. Ltd.; and patent application of agent for treatment of pediatric hypozincemia. TH reports grants for clinical research from Sysmex Corporation, Otsuka Pharmaceutical Co. Ltd., and Zenyaku Kogyo Co. Ltd.. TS has nothing to disclose. TY has nothing to disclose. RH has nothing to disclose. YO reports honoraria for lectures from ARKRAY, Inc., Merck & Co., Inc., and SHIONOGI & CO., LTD.. ST has nothing to disclose. KK reports grants for clinical research from Public Foundation of Vaccination Research Center, Taiju Life Social Welfare Foundation, Chugai Pharmaceutical Co. Ltd., Teijin Pharma Ltd., Kyowa Kirin Co. Ltd., Taiho Pharmaceutical Co. Ltd., Shionogi & Co. Ltd., Daiichi Sankyo Co. Ltd., Mitsubishi Tanabe Pharma Co. Ltd., and Otsuka Pharmaceutical Co. Ltd.; honoraria for lectures from Terumo Co. Ltd., Baxter Ltd., Zenyaku Kogyo Co. Ltd.. RT has nothing to disclose. YK has nothing to disclose. TK has nothing to disclose. YS has nothing to disclose. TM has nothing to disclose. AI has nothing to disclose. SF has nothing to disclose. MO has nothing to disclose. HK has nothing to disclose. AK has nothing to disclose. CN has nothing to disclose. KNa reports consulting fees from Kyowa Kirin Co. Ltd. and AstraZeneca; honoraria for lectures from Kyowa Kirin Co. Ltd. and Novartis; and serves as the president of the Japanese Society for Pediatric Nephrology. KIs reports grants for clinical research from Asahi Kasei Pharma Corporation, Chugai Pharmaceutical Co., Ltd., Novartis International AG, Japan Blood Products Organization, Teijin Pharma Limited, and Astellas Pharma Inc.; consulting fee from Chugai Pharmaceutical Co., Ltd.; honoraria for lectures from Zenyaku Kogyo Co. Ltd., Novartis International AG, and Teijin Pharma Limited. SI reports grants from Zenyaku Kogyo, Co., Ltd., Chuigai Pharmaceutical Co. Ltd., Astellas Pharma Inc., and Asahi Kasei Pharma Corporation; consulting fee from Zenyaku Kogyo Co. Ltd.; honoraria from Zenyaku Kogyo, Co., Ltd., Chuigai Pharmaceutical Co. Ltd., Novartis International AG, Asahi Kasei Pharma Corporation, and Astellas Pharma Inc.. HN reports grants for regulatory science on facilitating pediatric drug development from Japan Agency for Medical Research and Development; consulting fees from Tohoku University, Daiichi Sankyo Company, Limited, and Pfizer R&D Japan G.K.; Honoraria for lectures from Japan Pharmaceutical Manufacturers Association, Pfizer Global Supply Japan Inc., Bristol Myers Squibb Company, Chugai Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Northern Science Consulting Inc.; and serves as a member of advisory board of Taisho Pharmaceutical Holdings Co., Ltd. for drug development for diabetes, a member of advisory board of Sato Pharmaceutical Co., Ltd. for drug development for dermatology, Chairman of the Committee on Pharmaceutical Affairs of Japan Pediatric Society, and Chairman of the Steering Committee of Japan Society on Developmental Pharmacology and Therapeutics. GMG has nothing to disclose. RM has nothing to disclose. TO has nothing to disclose. KN reports a research grant for clinical trials and clinical research from Zenyaku Kogyo Co. Ltd. to his institution; consulting fees from Kyowa Kirin Co. Ltd., Toa Eiyo LTD., Zenyaku Kogyo Co. Ltd., and Taisho Pharmaceutical Co. Ltd.; honoraria for lectures from Ono Pharma, Astellas Pharma, Novo Nordisk Pharma, Alexion Pharma, Sumitomo Pharma, Sanofi, Otsuka Pharma, Daiichi Sankyo, and Miyarisan; and serves as a member of the advisory board of Kyowa Kirin Co. Ltd..","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"34306"}}